While many leverage precision medicine, Faeth is banking on precision nutrition to tackle cancer

The San Francisco-based biotech is pairing metabolically-engineered diets with existing therapies to starve and kill tumors.

By Karissa Waddick • March 9, 2023

Launched with a ‘pioneer’ in RNA, aTyr Pharma is charting a new course in immunology

With a focus on rare and hard-to-treat diseases, aTyr is banking on its head start in tRNA and vast IP portfolio to build a billion-dollar company.

By Taren Grom • March 2, 2023

Cytokinetics looks to muscle into the cardiovascular market

With a scientific platform based on muscle biology, the late-stage biotech is addressing cardiovascular and neuromuscular diseases.

By Taren Grom • Feb. 24, 2023

Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies

Jacopo Leonardi’s latest venture is in the burgeoning field of macrophage inhibitors that could target a wide range of cancers.

By Taren Grom • Feb. 17, 2023

Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm

The Israeli biotech just entered into a collaboration with Merck to develop its own checkpoint inhibitor alongside the bestselling cancer treatment.

By Michael Gibney • Feb. 16, 2023

Astria Therapeutics’ edge in an ultra-rare disease

With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.

By Taren Grom • Feb. 1, 2023

Galecto has identified a master switch to reduce fibroid formation

With expertise surrounding a natural family of proteins and enzymes that can lead to fibrosis, Galecto is exploring the potential to develop cancer treatments.

By Taren Grom • Jan. 11, 2023

Chinook Therapeutics nears the finish line in kidney disease

A company focused on kidney disease, Chinook is growing into a commercial outfit as its lead candidate approaches the market.

By Michael Gibney • Jan. 10, 2023

Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck

The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.

By Taren Grom • Jan. 9, 2023

Evommune’s unique method of drug discovery is more than skin deep

The biotech is using human skin squares from plastic surgery to find the best immunological molecules for solving conditions like dermatitis.

By Michael Gibney • Nov. 29, 2022

The first company to use Nobel-winning click chemistry in humans is on a mission to transform oncology

Shasqi founder and CEO José Mejía Oneto on how the company’s approach could provide a more effective alternative to ADCs and other emerging cancer therapies.

By Karissa Waddick • Oct. 27, 2022

Citius Pharmaceuticals sees golden opportunities in late-stage specialty assets

CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.

By Karissa Waddick • Oct. 11, 2022

Biotech spotlight: Twist Bioscience aims to remove limits on drug discovery with DNA synthesis platform

As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.

By Kim Ribbink • June 30, 2022

Biotech spotlight: Karuna Therapeutics’ mission to rejuvenate the field of neuroscience

An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.

By Kim Ribbink • June 16, 2022

Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach

Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.

By Michael Gibney • May 17, 2022

Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia

With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.

By Taren Grom • May 9, 2022

How OliX Pharmaceuticals is riding the RNAi wave

While the company may look like “the new kid on the block,” CEO Dong-ki Lee says the Korean biotech is ready for the global stage.

By Karissa Waddick , Taren Grom • April 25, 2022